Compare Cassava Sciences Inc (FLNA) vs SpaceX (SPCX) Price & Performance

FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.

Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.

SPCX trades at $134.95, down 0.83% and below its $135 IPO price for the first time. The stock shows bearish technical signals with negative earnings momentum (Q1 2026 EPS miss of -$1.19 vs -$0.33 expected) and widening losses (2026 net profit margin projected at -45%). Despite 100% analyst buy ratings and a $241.50 consensus target, high valuations (P/S 91.64, EV/EBITDA 951.8) and accelerating capital expenditures create significant investor skepticism.

The outlook remains challenged by substantial operational losses and cash burn, though long-term growth potential in space technology offers speculative upside. Key risks include execution on costly projects, competitive pressure, and dependency on future revenue streams to justify current valuation.